Clinical News

Clinical Status

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">Celgosivir: Completed Phase II enrollment</h1><div class="byline">WIR Staff</div><div class="date"></div></div></div></div>

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

MGI completed the enrollment of 43 patients in its open-label, dose-ranging Phase II trial. ......

Hepatic

Infectious

Celgosivir: Completed Phase II enrollment

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery: Disruptive Innovation

Distillery

Hot Topics

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

BioCentury Grand Rounds 2024

BioCentury Grand Rounds

The BioCentury-BayHelix China Healthcare Summit

BioCentury-BayHelix China Healthcare Summit

BioCentury-BIA Jefferies 2024

The BioCentury-BayHelix East-West BioPharma Summit

BioCentury-BayHelix East-West Summit

Bio€quity Europe

The BioCentury Show

Webinars - Upcoming & On-Demand

Events

My Workspace

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Request a Trial

Request a Subscription

Sponsorship & Branding Inquiry 

Media Kit

Request BioCentury's BCIQ Brochure

Customer Resource Center

Career Opportunities

Contact

Home